Clinical applicability of T-cell interferon-α release assay for tumour necrosis factor-α inhibitor therapy in severe psoriasis

Clinical and Experimental Dermatology

Volumn 36, Issue 1, 2011, Pages 39-41

  Chiang, Y Z ^a   Panting, K ^a   Dever, B ^a   Parslew, R A G ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BCG VACCINE; GAMMA INTERFERON; INFLIXIMAB; ISONIAZID; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; RISK FACTOR; SENSITIVITY ANALYSIS; SKIN TEST; T CELL INTERFERON ALPHA RELEASE ASSAY; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TRAVEL; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78650183070     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03850.x     Document Type: Article

References (10)

1. Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-97.
2. Roach DR, Bean AGD, Demangei C et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168: 4620-7.
3. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab - a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
4. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 2005; 60: 800-5.
5. Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the elimination of tuberculosis. MMWR Recomm Rep 1995; 44 (RR-11): 18-34.
6. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160: 8-15.
7. Perez JL, Kupper H, Spencer-Green G. Impact of screening for latent TB prior to initiation anti-TNF therapy in North America and Europe. Ann Rheum Dis 2005; 64 (Suppl. I:II): 86.
8. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72.
9. Lee YJ, Choi HJ, Park I-N et al. Comparison of two commercial interferon-γ assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28: 24-30.
10. Piana F, Codecasa LR, Cavallerio P et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006; 28: 31-4.